OS Therapies Inc
OSTX NYSE Pharmaceutical Preparations Financials FY2023–FY2025
Last close · Oct 23, 2026
$1.25
0.0%What OS Therapies Inc does
No business description yet.
- Legal name
- OS Therapies Inc
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Accession · CIK
- 0001213900-26-036629
0001795091
Revenue and margins
OS Therapies Inc had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$14.7M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
OS Therapies Inc returned — to shareholders in fiscal 2025. The diluted share count rose 320.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably OS Therapies Inc can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $0.0M | $5.5M | $0.3M |
| Interest coverage | −1.3x | −3.3x | — |
| Current ratio | 0.0x | 1.2x | 0.0x |
| Quick ratio | 0.0x | 1.2x | 0.0x |
| Total assets | $0.8M | $5.5M | $6.8M |
| Total liabilities | $24.8M | $4.7M | $11.9M |
| Shareholders' equity | −$24.0M | −$3.3M | −$6.1M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✕ |
| Share count didn't rise | — | — | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 5 | — / 6 |
| Accruals ratio | −599.5% | −50.5% | −234.5% |
| Altman Z'' | −354.80 | −30.54 | −71.73 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | $3.2M | $2.8M | $16.4M |
| Operating income | −$4.3M | −$6.8M | −$28.7M |
| Interest expense | $3.4M | $2.1M | — |
| Net income | −$7.8M | −$8.9M | −$28.8M |
| Net income to common | −$7.9M | −$8.9M | −$28.8M |
| Diluted EPS | −$1.46 | −$1.28 | −$0.98 |
| Diluted shares | — | 0.01B | 0.03B |
| Cash flow | |||
| Cash from operations | −$3.0M | −$7.3M | −$14.2M |
| Capital expenditure | — | — | $0.5M |
| Free cash flow | — | — | −$14.7M |
| Depreciation and amortization | $0.0M | $0.0M | $0.4M |
| Stock-based compensation | $0.0M | $0.3M | $4.3M |
| Balance sheet | |||
| Cash and short-term investments | $0.0M | $5.5M | $0.3M |
| Deposits | — | $0.2M | — |
| Current assets | $0.8M | $5.5M | $0.3M |
| Current liabilities | $24.7M | $4.6M | $11.8M |
| Property and equipment, net | $0.0M | $0.0M | $0.0M |
| Intangible assets | $0.0M | — | $6.5M |
| Total assets | $0.8M | $5.5M | $6.8M |
| Total liabilities | $24.8M | $4.7M | $11.9M |
| Preferred stock | $0.0M | — | — |
| Shareholders' equity | −$24.0M | −$3.3M | −$6.1M |
| Returns | |||
| Return on capital employed | 18.2% | −747.5% | 582.9% |
| Return on assets | −976.3% | −280.4% | −464.6% |
| Growth | |||
| Share count change | — | — | 320.9% |
| Financial health | |||
| Interest coverage | −1.3x | −3.3x | — |
| Current ratio | 0.0x | 1.2x | 0.0x |
| Quick ratio | 0.0x | 1.2x | 0.0x |
| Quality scores | |||
| Altman Z'' | −354.8 | −30.5 | −71.7 |
| Accruals ratio | −599.5% | −50.5% | −234.5% |
Source: SEC EDGAR XBRL filings (CIK 0001795091). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.